131 related articles for article (PubMed ID: 24078674)
1. Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et al.
van der Maas A; van Herwaarden N; den Broeder AA
Ann Rheum Dis; 2014 Jan; 73(1):e4. PubMed ID: 24078674
[No Abstract] [Full Text] [Related]
2. Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al.
Yoshida K; Sung YK; Kavanaugh A; Bae SC; Weinblatt ME; Kishimoto M; Matsui K; Tohma S; Solomon DH
Ann Rheum Dis; 2014 Jan; 73(1):e5. PubMed ID: 24152418
[No Abstract] [Full Text] [Related]
3. Biologic discontinuation studies: a systematic review of methods.
Yoshida K; Sung YK; Kavanaugh A; Bae SC; Weinblatt ME; Kishimoto M; Matsui K; Tohma S; Solomon DH
Ann Rheum Dis; 2014 Mar; 73(3):595-9. PubMed ID: 23723316
[TBL] [Abstract][Full Text] [Related]
4. Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al.
Bredemeier M
Ann Rheum Dis; 2014 Jun; 73(6):e33. PubMed ID: 24595549
[No Abstract] [Full Text] [Related]
5. Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.
Tweehuysen L; van den Ende CH; Beeren FM; Been EM; van den Hoogen FH; den Broeder AA
Arthritis Rheumatol; 2017 Feb; 69(2):301-308. PubMed ID: 27696778
[TBL] [Abstract][Full Text] [Related]
6. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases.
Souto A; Maneiro JR; Gómez-Reino JJ
Rheumatology (Oxford); 2016 Mar; 55(3):523-34. PubMed ID: 26490106
[TBL] [Abstract][Full Text] [Related]
7. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T
Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065
[TBL] [Abstract][Full Text] [Related]
8. [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].
Mallick A; Fautrel B; Sagez F; Sordet C; Javier RM; Petit H; Chatelus E; Rahal N; Gottenberg JE; Sibilia J
Rev Med Interne; 2017 Apr; 38(4):256-263. PubMed ID: 28161110
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review.
Letarouilly JG; Salmon JH; Flipo RM
Expert Opin Drug Saf; 2021 Sep; 20(9):1087-1094. PubMed ID: 33926364
[No Abstract] [Full Text] [Related]
10. Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis.
Koduri GM; Mukhtyar C
Rheumatology (Oxford); 2019 Apr; 58(4):559-560. PubMed ID: 29672739
[No Abstract] [Full Text] [Related]
11. [Early use of biological agents after first DMARD in rheumatoid arthritis - no].
Keyßer G
Dtsch Med Wochenschr; 2013 Dec; 138(50):2620. PubMed ID: 24301498
[No Abstract] [Full Text] [Related]
12. [Early use of biological agents after first DMARD in rheumatoid arthritis - no].
Thomann U
Dtsch Med Wochenschr; 2013 Dec; 138(50):2620. PubMed ID: 24301497
[No Abstract] [Full Text] [Related]
13. [Early use of biological agents after first DMARD in rheumatoid arthritis--no].
Keyßer G
Dtsch Med Wochenschr; 2013 Sep; 138(37):1851. PubMed ID: 24006169
[No Abstract] [Full Text] [Related]
14. Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.
Conn DL
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1622-3; author reply 1623-4. PubMed ID: 23024030
[No Abstract] [Full Text] [Related]
15. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation.
Iwamoto T; Ikeda K; Hosokawa J; Yamagata M; Tanaka S; Norimoto A; Sanayama Y; Nakagomi D; Takahashi K; Hirose K; Sugiyama T; Sueishi M; Nakajima H
Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1576-81. PubMed ID: 24515410
[TBL] [Abstract][Full Text] [Related]
16. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2014 Dec; 56(1458):127-32. PubMed ID: 25519024
[No Abstract] [Full Text] [Related]
17. Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.
Graudal N; Jürgens G
Arthritis Care Res (Hoboken); 2013 May; 65(5):832. PubMed ID: 23097263
[No Abstract] [Full Text] [Related]
18. Response to Dr Bredemeier's letter.
Vital EM; Dass S; Buch MH; Rawstron AC; Emery P
Ann Rheum Dis; 2014 Jun; 73(6):e34. PubMed ID: 24632007
[No Abstract] [Full Text] [Related]
19. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
20. [Rheumatic ailments. Can arthritis drugs be tapered?].
Füessl HS; Stiefelhagen P
MMW Fortschr Med; 2015 Oct; 157(17):31. PubMed ID: 26759868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
